California-Arizona Clinical Trials Network Node

描述（由申请人提供）：加州大学旧金山分校（UCSF）提出一项合作协议，以领导国家药物滥用治疗临床试验网络研究所（CTN）的一个节点。研究节点的总体目标是参与和开展药物滥用和成瘾干预措施的高质量多地点临床试验，并指导该领域有效干预措施的制定、传播和采用。我们的研究节点将由UCSF的区域研究和培训中心（PRTC）组成，该中心与亚利桑那大学的研究人员以及加利福尼亚州和亚利桑那州的社区治疗计划（ctp）合作。我们的加州-亚利桑那州研究节点将促进研究，以提高对阿片类药物、可卡因和甲基苯丙胺、尼古丁和其他滥用药物成瘾治疗的有效性。研究和治疗之间的差距是药物滥用中最关键的未解决问题之一。该节点将促进科学家和实践者之间的合作，以促进新的研究，提高社区环境中药物滥用治疗的有效性。拟建研究节点的目标是：(1)参与药物滥用和成瘾的行为、药理和联合治疗的临床试验；(2)与国家CTN领导层合作，开发和实施研究，特别关注艾滋病、吸烟和丙型肝炎等共同发生问题的患者；并开发和维护(3)管理基础设施(4)研究基础设施和(5)临床基础设施来实现这些目标。NIDA CTN可以在缩小药物滥用研究与治疗之间的差距方面发挥重要作用。这个研究节点有可能在未来十年加速临床试验和转化研究的进展。

DESCRIPTION (provided by applicant): The University of California, San Francisco (UCSF) proposes a cooperative agreement to lead a node in the National Institute on Drug Abuse Treatment Clinical Trials Network (CTN). The overall goal of the Research Node is to participate in and conduct high-quality multi-site clinical trials of interventions for drug abuse and addiction and to guide the development, dissemination, and adoption of effective interventions in the field. Our Research Node will consist of a Regional Research and Training Center (PRTC) at UCSF that is linked in partnership with researchers at the University of Arizona and with community-based treatment programs (CTPs) in California and Arizona. Our California-Arizona Research Node will stimulate research to improve the effectiveness of treatment of addiction to opiates, cocaine and methamphetamine, nicotine, and other abused drugs. The gap between research and treatment is one of the most critical unresolved issues in drug abuse. The Node will foster collaboration among scientists and practitioners to stimulate new research improving the effectiveness of drug abuse treatment in community settings. The aims for the proposed Research Node are: (1) to participate in clinical trials of behavioral, pharmacological, and combined therapies for drug abuse and addiction; (2) to work with the national CTN leadership in development and implementation of research studies with special attention to patients with such co-occurring problems such as HIV, smoking, and hepatitis C; and to develop and maintain (3) an administrative infrastructure (4) a research infrastructure, and (5) a clinical infrastructure to accomplish these aims. The NIDA CTN can have a significant role in closing the gap between research and treatment in drug abuse. This Research Node has the potential to accelerate the advance of clinical trials and translational research over the coming decade.